1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Psoriasis 2017

Psoriasis 2017

  • July 2017
  • ID: 4201020
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents


Will biosimilar anti-TNFs prevent novel therapies from gaining traction?

As the use of biosimilar anti-TNFs continues to expand access , and lower the costs of, biologic therapies in the treatment for psoriasis, is there room for novel products, such as the anti-interleukin-(IL)-17 mAbs and next-generation anti-IL23 mAbs? What about recently approved products, such as Siliq/Kyntheum (brodalumab), and Tremfya (guselkumab; Janssen/MorphoSys)? Clinical and commercial differentiation will become critical and as the treatment landscape becomes more crowded. Learn how KOLs see the market evolving, how current products can protect market share, and how developers can differentiate their pipeline therapies in KOL Insight: Psoriasis. Twelve North American and European KOLs provide their insight on 11 marketed products and over 15 pipeline programmes.

Take a tour of the report now:

Methodology >
Research Objectives >
Questions Asked >
See the RCC therapies covered >
Find out who the 6 US and 6 European KOLs are >
Sample Pages >

Top Takeaways

What does the future hold for branded anti-TNFs? Anti-TNFs have the most long-term safety and efficacy data to substantiate their clinical use, with Humira (adalimumab; AbbVie) being the ‘go-to’ drug in this category for many KOLs. But with several anti-TNF biosimilars scooping up market share, and more on the way, what does the future hold for branded anti-TNFs?
What impact will next-generation anti-IL23 mAbs have on the treatment landscape? KOLs are impressed with anti-IL12/23 mAbs, such as Stelara (ustekinumab; Janssen Biotech), but can newer drugs in this category, such as Tremfya (guselkumab; Janssen Biotech/MorphoSys), move things on even further? And will the lack of long-term real-world safety data hamper near-term commercial dynamics?
How do KOLs describe the anti-IL17 mAbs? Safe, effective, quick? What concerns remain, particularly for products with chequered development histories and the emergence of rare adverse effects such as IBD and Crohn’s disease? KOLs predict a future tussle between the anti-IL17 mAbs, but with which class of product?
Will payers influence the uptake of pipeline psoriasis drugs? If so, will this be based purely on cost and benefit of biosimilars, or do KOLs expect payers to look more closely at the data and allow patients to gain access to more effective treatments?
What have KOLs asked for from future treatments for psoriasis? Would KOLs prefer drugs that demonstrate long-term safety and disease remission, ones that allow for dosage flexibility and personalisation of treatment, or ones that are effective on the skin as well as joints?
Does the psoriasis treatment landscape have a differentiation problem? With many treatments available, and more on the way, what are KOLs most concerned about? What could help physicians make better treatment decisions so that patient care is optimised?

Quotes

“Certainly there’s no direct comparison, but on paper it [brodalumab] is more effective versus placebo than compared to secukinumab and ixekizumab. It genuinely does have a different mode of action, so there is a reason to use it after secukinumab or ixekizumab has failed because it almost gives you a bit more justification, you’re not just using another IL17 blocker.”
EU Key Opinion Leader

“The more you switch the risk of immunogenicity will increase. We have no concerns with Enbrel biosimilars, but Infliximab and adalimumab have immunogenic potential, and I would not like to risk the [loss of] response of the patient. I will have no problems to initiate a drug from the beginning.”
US Key Opinion Leader

Sample of therapies covered

Marketed Therapies

Taltz (ixekizumab; Eli Lilly)
Benepali (etanercept; Biogen/Samsung Bioepis)
Remsima (infliximab; Celltrion/Napp/Mundipharma)
Inflectra (infliximab; Pfizer/Celltrion)
Cosentyx (secukinumab; Novartis)
Otezla (apremilast; Celgene)
Stelara (ustekinumab; Janssen Biotech)
Humira (adalimumab; AbbVie)
Remicade (infliximab; Janssen Biotech/Merck & Co.)
Enbrel (etanercept; Amgen/Pfizer)

Pipeline Therapies

Siliq/Kyntheum (brodalumab; Leo Pharma/AstraZeneca)
Tremfya (guselkumab; Janssen Biotech/MorphoSys)
Amgevita/Amjevita (adalimumab; Amgen)
Erelzi (etanercept; Sandoz)
BI 695501 (adalimumab; Boehringer Ingelheim)
Tildrakizumab (Merck & Co./Sun Pharma)
Xeljanz (tofacitinib; Pfizer)
Imraldi (adalimumab; Biogen/Samsung Bioepis)
Cimzia (certolizumab pegol; UCB)
Risankizumab (Boehringer Ingelheim/AbbVie)
Piclidenoson (Can Fite Biopharma)
Mirikizumab (Eli Lilly)
Namilumab (Takeda)
Bimekizumab (UCB)
Various adalimumab and etanercept biosimilars (e.g. M923, MSB11022)

KOLs from North America

Steven R. Feldman. Professor of Dermatology, Professor of Pathology, Professor of Public Health Sciences - Social Science and Health Policy, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.
Jeffrey M Weinberg. Associate Clinical Professor Dermatology, Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Alan Menter. Dermatologist and Program Director, Dermatology Residency Program, Baylor University Medical Center, Baylor University, Dallas, Texas.
Robert T Brodell. Professor and Chair, Department of Dermatology, and Professor and Interim Chair of the Department of Pathology, University of Mississippi Medical Center, Jackson, Mississippi.
Bryan Cho. Dermatologist and Geneticist, Department of Dermatology, University of California, San Francisco.
Craig Leonardi. Associate Clinical Professor of dermatology at St. Louis University Medical School, St. Louis, Missouri.

KOLs from Europe

Puig Sanz. Director of the Department of Dermatology, Hospital de la Santa Creu i Sant Pau, an academic hospital which is affiliated with the Autonomous University of Barcelona.
Pablo Coto-Segura. Associate Professor of Dermatology, Hospital Universitario Central Asturias, Oviedo, Spain
Andrew Pink. Consultant Dermatologist, Guys and St. Thomas Hospital NHS Foundation Trust, London.
Richard Warren. Reader and Honorary Consultant Dermatologist, Division of Musculoskeletal & Dermatological Sciences, University of Manchester, UK
Odile Picard. Consultant at Saint Antoine Hospital in Paris, Professor of Dermatology at University of Saint-Antoine, France.
Anonymous German KOL. Professors and heads of a division with a specific focus on the treatment of inflammatory conditions, including psoriasis, at leading teaching hospitals in Germany.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Monoclonal Antibody Markets in China

Monoclonal Antibody Markets in China

  • $ 4000
  • October 2019

China’s demand for Monoclonal Antibody has grown at a fast pace in the past decade.In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth ...

Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2019

Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2019’; Interleukin ...

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2019: Deal trends, players and financials

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2019: Deal trends, players and financials

  • $ 2995
  • November 2019

The Global Cancer Monoclonal Antibody Partnering 2014-2019: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals ...


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on